Osteogenic molecules for clinical applications: improving the BMP-collagen system

Among the osteogenic growth factors used for bone tissue engineering, bone morphogenetic proteins (BMPs) are the most extensively studied for use in orthopaedic surgery. BMP-2 and BMP-7 have been widely investigated for developing therapeutic strategies and are the only two approved for use in sever...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Arrabal,Pilar M, Visser,Rick, Santos-Ruiz,Leonor, Becerra,José, Cifuentes,Manuel
Lenguaje:	English
Publicado:	Sociedad de Biología de Chile 2013
Materias:	BMPs collagen FGF-2 growth factors osteogenesis recombinant proteins RGD peptide
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602013000400013
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0716-97602013000400013
record_format	dspace
spelling	oai:scielo:S0716-976020130004000132014-02-05Osteogenic molecules for clinical applications: improving the BMP-collagen systemArrabal,Pilar MVisser,RickSantos-Ruiz,LeonorBecerra,JoséCifuentes,Manuel BMPs collagen FGF-2 growth factors osteogenesis recombinant proteins RGD peptide Among the osteogenic growth factors used for bone tissue engineering, bone morphogenetic proteins (BMPs) are the most extensively studied for use in orthopaedic surgery. BMP-2 and BMP-7 have been widely investigated for developing therapeutic strategies and are the only two approved for use in several clinical applications. Due to the chemical and biological characteristics of these molecules, their authorised uses are always in combination with a carrier based on collagen type I. Although the use of these growth factors is considered safe in the short term, the very high doses needed to obtain significant osteoinduction make these treatments expensive and their long-term safety uncertain, since they are highly pleiotropic and have the capacity to induce ectopic ossification in the surrounding tissues. Therefore it is necessary to improve the currently used BMP-collagen system in terms of efficiency, biosecurity and costs. There are several strategies to increase the clinical effectiveness of these treatments. In this review we summarize the most promising results and our related work focused on this field through two different approaches: i) the development of recombinant BMPs with additional features, and ii) complementing these systems with other growth factors or molecules to enhance or accelerate osteogenesisinfo:eu-repo/semantics/openAccessSociedad de Biología de ChileBiological Research v.46 n.4 20132013-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602013000400013en10.4067/S0716-97602013000400013
institution	Scielo Chile
collection	Scielo Chile
language	English
topic	BMPs collagen FGF-2 growth factors osteogenesis recombinant proteins RGD peptide
spellingShingle	BMPs collagen FGF-2 growth factors osteogenesis recombinant proteins RGD peptide Arrabal,Pilar M Visser,Rick Santos-Ruiz,Leonor Becerra,José Cifuentes,Manuel Osteogenic molecules for clinical applications: improving the BMP-collagen system
description	Among the osteogenic growth factors used for bone tissue engineering, bone morphogenetic proteins (BMPs) are the most extensively studied for use in orthopaedic surgery. BMP-2 and BMP-7 have been widely investigated for developing therapeutic strategies and are the only two approved for use in several clinical applications. Due to the chemical and biological characteristics of these molecules, their authorised uses are always in combination with a carrier based on collagen type I. Although the use of these growth factors is considered safe in the short term, the very high doses needed to obtain significant osteoinduction make these treatments expensive and their long-term safety uncertain, since they are highly pleiotropic and have the capacity to induce ectopic ossification in the surrounding tissues. Therefore it is necessary to improve the currently used BMP-collagen system in terms of efficiency, biosecurity and costs. There are several strategies to increase the clinical effectiveness of these treatments. In this review we summarize the most promising results and our related work focused on this field through two different approaches: i) the development of recombinant BMPs with additional features, and ii) complementing these systems with other growth factors or molecules to enhance or accelerate osteogenesis
author	Arrabal,Pilar M Visser,Rick Santos-Ruiz,Leonor Becerra,José Cifuentes,Manuel
author_facet	Arrabal,Pilar M Visser,Rick Santos-Ruiz,Leonor Becerra,José Cifuentes,Manuel
author_sort	Arrabal,Pilar M
title	Osteogenic molecules for clinical applications: improving the BMP-collagen system
title_short	Osteogenic molecules for clinical applications: improving the BMP-collagen system
title_full	Osteogenic molecules for clinical applications: improving the BMP-collagen system
title_fullStr	Osteogenic molecules for clinical applications: improving the BMP-collagen system
title_full_unstemmed	Osteogenic molecules for clinical applications: improving the BMP-collagen system
title_sort	osteogenic molecules for clinical applications: improving the bmp-collagen system
publisher	Sociedad de Biología de Chile
publishDate	2013
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602013000400013
work_keys_str_mv	AT arrabalpilarm osteogenicmoleculesforclinicalapplicationsimprovingthebmpcollagensystem AT visserrick osteogenicmoleculesforclinicalapplicationsimprovingthebmpcollagensystem AT santosruizleonor osteogenicmoleculesforclinicalapplicationsimprovingthebmpcollagensystem AT becerrajose osteogenicmoleculesforclinicalapplicationsimprovingthebmpcollagensystem AT cifuentesmanuel osteogenicmoleculesforclinicalapplicationsimprovingthebmpcollagensystem
_version_	1718441508387946496

Osteogenic molecules for clinical applications: improving the BMP-collagen system

Ejemplares similares